Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Bessemer Group Inc.

Bessemer Group Inc. grew its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 451.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 782,856 shares of the company's stock after purchasing an additional 640,865 shares during the quarter. Bessemer Group Inc. owned approximately 0.09% of Dr. Reddy's Laboratories worth $12,361,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. AIA Group Ltd lifted its holdings in shares of Dr. Reddy's Laboratories by 441.7% during the fourth quarter. AIA Group Ltd now owns 145,150 shares of the company's stock valued at $2,292,000 after purchasing an additional 118,357 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after buying an additional 3,911,404 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the period. Van ECK Associates Corp grew its stake in Dr. Reddy's Laboratories by 609.4% during the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after acquiring an additional 5,015 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Dr. Reddy's Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after purchasing an additional 427,573 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 0.8 %

NYSE RDY traded up $0.11 on Wednesday, reaching $13.43. 385,574 shares of the company were exchanged, compared to its average volume of 1,408,740. The business's fifty day moving average price is $13.17 and its 200 day moving average price is $14.33. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $11.21 billion, a P/E ratio of 21.39 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.26 and a fifty-two week high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.